Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Heuser, Michael
- Robak, Tadeusz
- Leber, Brian
- Fiedler, Walter
- Pollyea, Daniel A.
- Brown, Andrew M.
- O'Connell, Ashleigh
- Ma, Weidong Wendy
- Chan, Geoffrey
- Cortes, Jorge E.
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Keywords
- acute myeloid leukemia; myelodysplasia; clinical trial; glasdegib; AML
Campos de Estudio
Cita
Heuser,M,Robak,T,Montesinos,P,Leber,B,Fiedler,W,Pollyea,DA,Brown,AM et al. Glasdegib Plus Low-Dose Cytarabine in Acute Myeloid Leukemia or Myelodysplastic Syndrome: BRIGHT AML 1003 Final Report and 4-Year Overall Survival Follow-Up. 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931:CIG MEDIA GROUP, LP. 2020 p.p. 176-176.
Portal de investigación